Harold J. Burstein, Md, Phd, On Breast Cancer Treatment | Dana-Farber Cancer Institute

Harold J. Burstein, MD, PhD, on breast cancer treatment | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Harold Burstein, MD, PhD on advances in breast cancer research from ASCO 2022

Dana-Farber Cancer Institute

Harold Burstein, MD, PhD on key advances from ASCO 2022

Dana-Farber Cancer Institute

Dr. Harold Burstein at SABCS 2014 | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Burstein on the Treatment Landscape of HER2+ Breast Cancer

Does Pregnancy Reduce the Risk of Developing Breast or Gynecologic Cancers?

Dana-Farber Cancer Institute

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

Breast cancer highlights from the 2022 ASCO Annual Meeting | Harold Burstein

Medicine Matters oncology

Breast cancer research report from San Antonio | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

New Research in Metastatic Breast Cancer | SABCS 2019

Dana-Farber Cancer Institute

What is Neoadjuvant Therapy? | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

How and When Should Women Get Screened for Breast Cancer?

Dana-Farber Cancer Institute

Report from 2011 San Antonio Breast Cancer Symposium | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

What Is an Aromatase Inhibitor? | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Burstein Discusses Pathological Complete Response

278 ‒ Breast cancer: how to catch, treat, and survive breast cancer | Harold Burstein, M.D., Ph.D.

Does Breastfeeding Reduce Your Risk of Breast Cancer?

Dana-Farber Cancer Institute

How to treat HER2+ Breast Cancer in 2024 with Dr. Harold Burstein

OncBrothers: Practice-Changing Cancer Discussions

Dr. Hal Burstein on education seminars at ASCO 2012 | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Cancer expert explains targeted (biological) therapy for breast cancer

NCCN